Cingulate Q2 10-Q: $28.4M Cash, Going Concern Doubt, FDA CRL Details
CING sits 62% above its 52-week low of $3.16 on light trading volume (0.2× avg).
Summary
Cingulate's Q2 10-Q details a going concern warning, FDA manufacturing deficiencies for its lead drug, and ongoing dilutive financing, despite $28.4 million in cash.
Key Events · Earnings and Guidance · CING
-
Going Concern Doubt
Management states substantial doubt about the company's ability to continue as a going concern within one year after the financial statement issuance date.
-
FDA Complete Response Letter
The CRL for CTx-1301 identified specific Chemistry, Manufacturing and Controls (CMC) information requests; no clinical safety or efficacy concerns were raised.
-
CDMO Form 483
The FDA issued a Form 483 with three observations to the CDMO's facility in February 2026; two facility-related and one specific to CTx-1301.
-
Cash Runway
Cash and cash equivalents of $28.4 million as of June 30, 2026, expected to fund operations into mid-2027.
Analysis · CING · Life Sciences
Cingulate's 10-Q confirms the Q2 results but adds critical detail: the company has substantial doubt about its ability to continue as a going concern within one year. The filing also reveals the FDA's Complete Response Letter for CTx-1301 cited manufacturing deficiencies, and the CDMO received a Form 483 with three observations. While $28.4 million in cash provides runway into mid-2027, the company continues to raise capital through multiple dilutive mechanisms, including a $100 million ATM and a $25 million equity line with Lincoln Park. The going concern language and regulatory setbacks are the key risks for investors.
How filings like this one have moved
In the 30 days to Oct 14, 2026, 36.6% of the 951 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CING was trading at $5.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $70.2M. The 52-week trading range was $3.16 to $11.89. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.